International Journal of Gynecological Cancer

Difficult clinical decisions in gynecological oncology: identifying priorities for future clinical research
pp. 1-7(7)
Authors: HARRISON,; CARTER,; YOUNG,; SOLOMON,

Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature
pp. 8-15(8)
Authors: ZHAO,; HUANG,; LIAN,; LANG,

Gonadotropins and ovarian carcinogenesis: a new era of basic research and its clinical implications
pp. 16-22(7)
Author: KONISHI,

Primary peritoneal carcinoma: experience with cytoreductive surgery and combination chemotherapy
pp. 23-28(6)
Authors: NAM,; KIM,; JUNG,; YOO,; MOK,

A 10-year review of primary fallopian tube cancer at a community hospital: a high association of synchronous and metachronous cancers
pp. 29-35(7)
Authors: BENOIT,; HANNIGAN,

Sampling the omentum in ovarian neoplasia: when one block is enough
pp. 36-40(5)
Authors: DOIG,; MONAGHAN,

A decreasing incidence of ovarian carcinoma in Israel
pp. 41-44(4)
Authors: MENCZER,; LIPHSHITZ,; BARCHANA,

Comparison of diagnostic usefulness of predictive models in preliminary differentiation of adnexal masses
pp. 45-51(7)
Authors: MOSZYNSKI,; SZPUREK,; SMOLEN,; SAJDAK,

Paclitaxel–platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial
pp. 52-56(5)
Authors: UTSUNOMIYA,; AKAHIRA,; TANNO,; MORIYA,; TOYOSHIMA,; NIIKURA,; ITO,; MORIMURA,; WATANABE,; YAEGASHI,

Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer
pp. 57-64(8)
Authors: TIERSTEN,; SELLECK,; SMITH,; WERTHEIM,; KAUFMAN,; HERSHMAN,; VAHDAT,; SAVAGE,; MACARTHUR,; HESDORFFER,

Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer
pp. 65-70(6)
Authors: VERHAAR-LANGEREIS,; KARAKUS,; vanEIJKEREN,; VOEST,; WITTEVEEN,

A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer
pp. 71-76(6)
Authors: D'AGOSTINO,; DELCAMPO,; MELLADO,; IZQUIERDO,; MINARIK,; CIRRI,; MARINI,; PEREZ-GRACIA,; SCAMBIA,

Efficacy and tolerability of the ifosfamide–epirubicin combination in relapsed ovarian cancer
pp. 77-82(6)
Authors: JOLY,; BOURGEOIS,; FLOQUET,; CHINET-CHARROT,; MEYER,; LEBRUN,; HAMOND,; LEROY,; HERON,

Correlation of serum and ascitic IL-12 levels with second-look laparotomy results and disease progression in advanced epithelial ovarian cancer patients
pp. 83-86(4)
Authors: BOZKURT,; YUCE,; BASARAN,; GARIBOGLU,; KOSE,; AYHAN,

Impact of initial surgical access on staging and survival of patients with stage I ovarian cancer
pp. 87-94(8)
Authors: LÉCURU,; DESFEUX,; CAMATTE,; BISSERY,; BLANC,; QUERLEU,

A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy
pp. 95-100(6)
Authors: LEE,; MIN,; PARK,; KIM,; BAE,

Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy
pp. 101-105(5)
Authors: MOK,; KIM,; JUNG,; NAM,

Primary malignant mesodermal ovarian sarcomas
pp. 106-109(4)
Authors: GARI,; SOUHAMI,; ARSENEAU,; STANIMIR,

Growth regulation and transcriptional activities of estrogen and progesterone in human endometrial cancer cells
pp. 110-120(11)
Authors: GIELEN,; HANEKAMP,; HANIFI-MOGHADDAM,; SIJBERS,; vanGOOL,; BURGER,; BLOK,; HUIKESHOVEN,

Hormonal function after ovarian transposition to the abdominal subcutaneous fat tissue
pp. 121-124(4)
Authors: NAGAO,; FUJIWARA,; ISHIKAWA,; ODA,; TANAKA,; AOTANI,; KOHNO,

An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer
pp. 125-134(10)
Authors: BRYAN,; RADBOD,; BEREK,

Ethnicity is a factor to be considered before dose planning in ovarian cancer patients to be treated with topotecan
pp. 135-139(5)
Authors: TAM,; CHAN,; NG,; WONG,; NGAN,

Malignant transformation of ovarian mature cystic teratoma
pp. 140-144(5)
Authors: RIM,; KIM,; CHOI,

Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors
pp. 145-151(7)
Authors: DIMOVA,; ZAHARIEVA,; RAITCHEVA,; DIMITROV,; DOGANOV,; TONCHEVA,

p63 expression in epithelial ovarian tumors
pp. 152-155(4)
Authors: POLI NETO,; CANDIDO DOS REIS,; ZAMBELLI RAMALHO,; NOGUEIRA,; deANDRADE,

Procaspase-3 enhances the in vitro effect of cytosine deaminase–thymidine kinase disuicide gene therapy on human ovarian cancer
pp. 156-164(9)
Authors: SONG,; KONG,; MA,; QU,; JIANG,

Induction of G1 arrest and differentiation in MDA-MB-231 breast cancer cell by boehmeriasin A, a novel compound from plant
pp. 165-170(6)
Authors: YAN,; LUO,; GAO,; ZHANG,

Gonadotropins mediate DNA synthesis and protection from spontaneous cell death in human ovarian surface epithelium
pp. 171-177(7)
Authors: EDMONDSON,; MONAGHAN,; DAVIES,

Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis
pp. 178-182(5)
Authors: CHANG,; ALBARRACIN,; LUTHRA,; WANG,; ZHENG,; MALPICA,; DEAVERS,; SILVA,; LIU,

Prophylactic salpingo-oophorectomy in 51 women with familial breast–ovarian cancer: importance of fallopian tube dysplasia
pp. 183-188(6)
Authors: LEUNEN,; LEGIUS,; MOERMAN,; AMANT,; NEVEN,; VERGOTE,

CA19-9 may have clinical significance in mature cystic teratomas of the ovary
pp. 189-193(5)
Authors: DEDE,; GUNGOR,; YENEN,; ALANBAY,; DURU,; HAŞIMI,

Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay
pp. 194-201(8)
Authors: GALLION,; CHRISTOPHERSON,; COLEMAN,; DEMARS,; HERZOG,; HOSFORD,; SCHELLHAS,; WELLS,; SEVIN,

Analysis of gene expression patterns of ovarian cancer cell lines with different metastatic potentials
pp. 202-209(8)
Authors: BAI,; FENG,; CHENG,; SHI,; YANG,; CUI,

Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer
pp. 210-218(9)
Authors: WILEY,; KATSAROS,; FRACCHIOLI,; YU,

The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin^™) in chemoresistant ovarian cancer cells
pp. 219-221(3)
Authors: MENENDEZ,; VELLON,; LUPU,

Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP)
pp. 222-230(9)
Authors: GALLO,; FRUSCELLA,; FERLINI,; APOLLONIO,; MANCUSO,; SCAMBIA,

Irregularly shaped inclusion cysts display increased expression of Ki67, Fas, Fas ligand, and procaspase-3 but relatively little active caspase-3
pp. 231-239(9)
Authors: SLOT,; DE BOER-BROUWER,; VOORENDT,; SIE-GO,; GHAHREMANI,; DORRINGTON,; TEERDS,

Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies
pp. 240-252(13)
Authors: MELICHAR,; SOLICHOVÁ,; FREEDMAN,

Should punch biopsies be used when high-grade disease is suspected at initial colposcopic assessment? A prospective study
pp. 253-256(4)
Authors: BYROM,; DOUCE,; JONES,; TUCKER,; MILLINSHIP,; DHAR,; REDMAN,

A cytohistologic study of atypical glandular cells detected in cervical smears during cervical screening tests in Iran
pp. 257-261(5)
Authors: MOOD,; EFTEKHAR,; HARATIAN,; SAEEDI,; RAHIMI-MOGHADDAM,; YARANDI,

Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance
pp. 262-265(4)
Authors: KIATPONGSAN,; NIRUTHISARD,; MUTIRANGURA,; TRIVIJITSILP,; VASURATNA,; CHAITHONGWONGWATTHANA,; LERTKHACHONSUK,

Human papillomavirus and cervical cancer from a prospective study in Khon Kaen, Northeast Thailand
pp. 266-269(4)
Authors: SRIAMPORN,; SNIJDERS,; PIENTONG,; PISANI,; EKALAKSANANAN,; MEIJER,; PARKIN,

Development of anticancer gene vaccine interact with human papillomavirus oncoprotein inhibition
pp. 270-276(7)
Authors: AHN,; BAE,; LEE,; KIM,; NAMKOONG,; JIN,

Phase II study of the American Brachytherapy Society guidelines for the use of high–dose rate brachytherapy in the treatment of cervical carcinoma: is 45–50.4 Gy radiochemotherapy plus 31.8 Gy in six fractions high–dose rate brachytherapy tolerable?
pp. 277-282(6)
Authors: SHAKESPEARE,; LIM,; LEE,; BACK,; MUKHERJEE,; LU,

Unilateral groin and pelvic irradiation for unilaterally node-positive women with vulval carcinoma
pp. 283-287(5)
Authors: JACKSON,; FANKAM,; DAS,; NAIK,; LOPES,; GODFREY,; HATEM,; BRANSON,; TAYLOR,

Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix
pp. 288-293(6)
Authors: BRAND,; BULL,; CAKIR,

Long-standing complications after treatment for cancer of the uterine cervix—clinical significance of medical examination at 5 years after treatment
pp. 294-297(4)
Authors: MATSUURA,; KAWAGOE,; TOKI,; TANAKA,; KASHIMURA,

Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study
pp. 298-305(8)
Authors: SMITH,; JIANG,; WEISS,; HALLUM,; LIU,; ROBINSON,; CHENG,; SCUDDER,; MARKMAN,; ALBERTS,

Oxygenated and reoxygenated tumors show better local control in radiation therapy for cervical cancer
pp. 306-311(6)
Authors: SUZUKI,; NAKANO,; OHNO,; KATO,; NIIBE,; MORITA,; TSUJII,

Routine computerized tomography scanning, groin ultrasound with or without fine needle aspiration cytology in the surgical management of primary squamous cell carcinoma of the vulva
pp. 312-317(6)
Authors: LAND,; HEROD,; MOSKOVIC,; KING,; SOHAIB,; TROTT,; NASIRI,; SHEPHERD,; BRIDGES,; IND,; BLAKE,; BARTON,

Detection of chromosomal aberrations by fluorescence in situ hybridization in cervicovaginal biopsies from women exposed to diethylstilbestrol in utero
pp. 318-324(7)
Authors: HAJEK,; KING,; HERNÁNDEZ-VALERO,; KAUFMAN,; LIANG,; CHILTON,; EDWARDS,; WHARTON,; JONES,

HER-2 codon 655 polymorphism in cervical carcinogenesis
pp. 325-328(4)
Authors: UEDA,; HUNG,; TERAI,; SAITO,; NUNOBIKI,; NODA,; UEKI,

HOXB homeobox gene expression in cervical carcinoma
pp. 329-335(7)
Authors: LÓPEZ,; GARRIDO,; PIÑA,; HIDALGO,; LAZOS,; OCHOA,; SALCEDO,

Evidence of human papillomavirus infection, enhanced phosphorylation of retinoblastoma protein, and decreased apoptosis in sarcomatoid squamous cell carcinoma of uterine cervix
pp. 336-340(5)
Authors: LIN,; HO,; SHEN,; HUANG,; CHOU,

Suppression of telomerase activity and arrest at G1 phase in human cervical cancer HeLa cells by all-trans retinoic acid
pp. 341-346(6)
Authors: GUO,; XIAO,; KANG,; LIU,; CHEN,; ZHANG,

Overexpression of p16^INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia
pp. 347-353(7)
Authors: ISHIKAWA,; FUJII,; SAITO,; NINDL,; ONO,; KUBUSHIRO,; TSUKAZAKI,; MUKAI,; NOZAWA,

Pelvic floor dysfunction and radical hysterectomy
pp. 354-363(10)
Authors: JACKSON,; NAIK,

Pelvic exenteration without external urinary or fecal diversion in gynecological cancer patients
pp. 364-368(5)
Authors: UNGAR,; PALFALVI,

Urodynamic study on postsurgical bladder function in cervical cancer treated with systematic nerve-sparing radical hysterectomy
pp. 369-375(7)
Authors: TODO,; KUWABARA,; WATARI,; EBINA,; TAKEDA,; KUDO,; YAMAMOTO,; SAKURAGI,

How can we predict ureteral obstruction after gynecological surgery? The changes in Doppler resistive index and plasma creatinine and magnesium concentrations after surgical, unilateral ureteral obstruction in a rabbit model
pp. 376-379(4)
Authors: TEREK,; TAMSEL,; AYGUL,; AKMAN,; IRER,; ITIL,; ALPER,

Routine follow-up after treatment for a gynecological cancer: a survey of practice
pp. 380-384(5)
Authors: KEW,; CRUICKSHANK,

Preoperative and intraoperative assessment of myometrial invasion and histologic grade in endometrial cancer: role of magnetic resonance imaging and frozen section
pp. 385-390(6)
Authors: SANJUÁN,; COBO,; PAHISA,; ESCARAMÍS,; ORDI,; AYUSO,; GARCIA,; HERNÁNDEZ,; TORNÉ,; MARTÍNEZ ROMÁN,; LEJÁRCEGUI,; VANRELL,

Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma
pp. 391-395(5)
Authors: ARAI,; WATANABE,; KAWAGUCHI,; KAMATA,; NISHIMURA,; JOBO,; KURAMOTO,

Aggressive angiomyxoma of the female pelvis and perineum: a case series
pp. 396-401(6)
Authors: MAGTIBAY,; SALMON,; KEENEY,; PODRATZ,

Expression of cyclin H in normal and cancerous endometrium, its correlation with other cyclins, and association with clinicopathologic parameters
pp. 402-408(7)
Authors: KAYASELCUK,; ERKANLI,; BOLAT,; SEYDAOGLU,; KUSCU,; DEMIRHAN,

Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer
pp. 409-415(7)
Authors: KANASUGI,; AOKI,; SUZUKI,; SUSUMU,; NAKATA,; HORIUCHI,; UDAGAWA,; NOZAWA,

Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?
pp. 416-422(7)
Authors: RASPOLLINI,; SUSINI,; AMUNNI,; PAGLIERANI,; CASTIGLIONE,; GARBINI,; CARRIERO,; SCARSELLI,; TADDEI,

Clinical significance of N-acetyl-l-aspartate resonance in ovarian mucinous cystadenoma
pp. 423-426(4)
Authors: HASCALIK,; CELIK,; SARAC,; ALKAN,; MIZRAK,

Ovarian endometrioid carcinoma with diffuse pigmented peritoneal keratin granulomas: a case report and review of the literature
pp. 426-429(4)
Authors: WU,; CHANG,; HSUEH,; LAI,

Metastatic Hurthle cell carcinoma in the abdomen masquerading as a primary ovarian tumor: a case report
pp. 429-432(4)
Authors: AL-KHATIB,; SIEUNARINE,; LINDSAY,; SMITH,

Carcinosarcoma arising from atypical endometriosis in a cesarean section scar
pp. 432-435(4)
Authors: LENG,; LANG,; GUO,; LI,; LIU,

A case of Sertoli–Leydig cell tumor in a postmenopausal woman
pp. 435-438(4)
Authors: CARINGELLA,; LOIZZI,; RESTA,; FERRERI,; LOVERRO,

Large-cell neuroendocrine carcinoma of the cervix associated with cervical-type invasive adenocarcinoma: a report of case and discussion of histogenesis
pp. 438-442(5)
Authors: CETINER,; KIR,; AKOZ,; GURBUZ,; KARATEKE,

Metastatic uterine leiomyosarcoma coexisting with papillary carcinoma of the thyroid gland
pp. 442-445(4)
Authors: GIANNIKAKI,; MANTADAKIS,; MAMALAKI,; DELIDES,; SAMONIS,

Uterine lipoma and coincidental cervical cancer: a case report
pp. 445-447(3)
Authors: DILEK,; AKCIN,; ERDEM,; TIRAS,; DURSUN,

Use of Prolene Mesh in surgical treatment of tissue defects after radical inguinal and pelvic lymph node dissection in vulvar cancer—a brief report
pp. 448-451(4)
Author: OLEJEK,

Perioperative morbidity and mortality of gynecological oncologic surgery in elderly women
pp. 452-457(6)
Authors: BEN-AMI,; VAKNIN,; SCHNEIDER,; HALPERIN,

To the Editor
pp. 458-458(1)

Response to the letter of Barton
pp. 459-460(2)

Erratum
pp. 461-461(1)